{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:14:45Z","timestamp":1773342885475,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shizuoka Prefecture","award":["Nothing"],"award-info":[{"award-number":["Nothing"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by benign tumors in multiple organs, leading to significant morbidity. Despite its recognition as a rare disease in Japan, comprehensive regional epidemiological data are lacking, hindering effective healthcare resource allocation and the development of targeted therapies. This study aimed to determine the prevalence and epidemiological characteristics of TSC in Shizuoka Prefecture and assess the associated healthcare burden.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study using data from the Shizuoka Kokuho Database, covering approximately 2.4\u00a0million residents over an 8.5-year period (April 2012\u2013September 2020). TSC cases were identified using the International Classification of Diseases, 10th Revision (ICD-10) code Q85.1. Adjusted prevalence rates were calculated, and analyses were performed on patient demographics, healthcare utilization, comorbidities, and treatment patterns. Comparisons with the general population were made to assess differences in neurological and renal complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 125 patients diagnosed with TSC were identified, resulting in an adjusted prevalence rate of 10.2 per 100,000. Diagnosis rates increased after 2012, likely due to revised diagnostic criteria and the introduction of mammalian target of rapamycin (mTOR) inhibitors. Patients with TSC exhibited substantial healthcare utilization and significantly higher rates of neurological and renal complications compared to the general population. Disease prevalence was notably higher among young males and varied across different age groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The higher prevalence of TSC observed in Shizuoka Prefecture suggests potential underestimation in other regions. The findings underscore the need for enhanced diagnostic strategies, including widespread genetic testing and updated treatment protocols, to effectively manage the diverse manifestations of TSC. Continuous epidemiological monitoring and adaptive healthcare policies are essential to improve timely diagnosis and the overall quality of life for patients with TSC. This study supports the necessity of patient-centered approaches in managing chronic rare diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03799-w","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:02:06Z","timestamp":1748019726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidemiological insights and healthcare challenges of tuberous sclerosis complex in Shizuoka Prefecture: a retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Satoshi","family":"Kishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Miyachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"3799_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14924\/dermatol.128.1","volume":"128","author":"M Wataya-Kaneda","year":"2018","unstructured":"Wataya-Kaneda M, Mizuguchi M, Hatano T, Seyama Y, Hino O, Nishigori CH. Revised tuberous sclerosis complex diagnostic criteria and treatment guidelines [in Japanese]. Nippon Hifuka Gakkai Zasshi. 2018;128:1\u201316. https:\/\/doi.org\/10.14924\/dermatol.128.1.","journal-title":"Nippon Hifuka Gakkai Zasshi"},{"key":"3799_CR2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(05)60292-9","volume":"352","author":"F Callaghan","year":"1998","unstructured":"Callaghan F, Shiell A, Osborne J, Martyn C. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;352:318\u20139. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673605788723?via%3Dihub.","journal-title":"Lancet"},{"key":"3799_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/jmg.26.1.28","volume":"26","author":"J Sampson","year":"1989","unstructured":"Sampson J, Scahill S, Stephenson J, Mann L, Connor J. Genetic aspects of tuberous sclerosis in the West of Scotland. J Med Genet. 1989;26:28\u201331. https:\/\/jmg.bmj.com\/content\/26\/1\/28.","journal-title":"J Med Genet"},{"key":"3799_CR4","unstructured":"National Organization for Rare Disorders (NORD). Barriers to Rare Disease Diagnosis, Care and Treatment in the US: A 30-Year Comparative Analysis. 2020. https:\/\/rarediseases.org\/wp-content\/uploads\/2020\/11\/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf"},{"key":"3799_CR5","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1111\/apa.15974","volume":"110","author":"SC Groft","year":"2021","unstructured":"Groft SC, Posada M, Taruscio D. Progress, challenges and global approaches to rare diseases. Acta Paediatr. 2021;110:2711\u20136. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apa.15974.","journal-title":"Acta Paediatr"},{"key":"3799_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","volume":"11","author":"CP Austin","year":"2018","unstructured":"Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, et al. Future of rare diseases research 2017\u20132027: an IRDiRC perspective. Clin Transl Sci. 2018;11:21\u20137. https:\/\/doi.org\/10.1111\/cts.12500.","journal-title":"Clin Transl Sci"},{"key":"3799_CR7","unstructured":"Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendation of the 2012 international tuberous sclerosis complex consensus conference. Pediatric Neurology. 2013;48:255\u2013265. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0887899413004918?via%3Dihub"},{"issue":"5","key":"3799_CR8","doi-asserted-by":"publisher","first-page":"e63910","DOI":"10.1371\/journal.pone.0063910","volume":"8","author":"M Wataya-Kaneda","year":"2013","unstructured":"Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I. Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS ONE. 2013;8(5):e63910. https:\/\/doi.org\/10.1371\/journal.pone.0063910.","journal-title":"PLoS ONE"},{"key":"3799_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/088307380001501003","volume":"15","author":"S Jozwiak","year":"2000","unstructured":"Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000;15:652\u20139. https:\/\/doi.org\/10.1177\/088307380001501003.","journal-title":"J Child Neurol"},{"key":"3799_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"International Tuberous Sclerosis Complex Consensus Group","year":"2021","unstructured":"International Tuberous Sclerosis Complex Consensus Group. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50\u201366. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S088789942100151X?via%3Dihub.","journal-title":"Pediatr Neurol"},{"key":"3799_CR11","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20200480","author":"E Nakatani","year":"2021","unstructured":"Nakatani E, Tabara Y, Sato Y, Tsuchiya A, Miyachi Y. Data resource profile of Shizuoka Kokuho database (SKDB) using integrated health- and care-insurance claims and health checkups: the Shizuoka study. J Epidemiol. 2021. https:\/\/doi.org\/10.2188\/jea.JE20200480.","journal-title":"J Epidemiol"},{"key":"3799_CR12","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1038\/s41467-018-07460-y","volume":"9","author":"E Ferkingstad","year":"2018","unstructured":"Ferkingstad E, Oddsson A, Gretarsdottir S, Benonisdottir S, Thorleifsson G, Deaton AM, et al. Genome-wide association meta-analysis yields 20 loci associated with gallstone disease. Nat Commun. 2018;9:5101. https:\/\/www.nature.com\/articles\/s41467-018-07460-y.","journal-title":"Nat Commun"},{"key":"3799_CR13","unstructured":"Ohno Kosaku Y, Noriko, Takeshita Kenzo. Epidemiology of epiloia in Sannin district, Japan. Morbidity and birth rate. Fiscal Year 1996. 1997; 8\u201310. https:\/\/jglobal.jst.go.jp\/en\/detail?JGLOBAL_ID=200902199273946414"},{"key":"3799_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.seizure.2017.10.005","volume":"53","author":"KO Welin","year":"2017","unstructured":"Welin KO, Carlqvist P, Svensson A, Althin R, Eklund E, Rask O. Epilepsy in tuberous sclerosis patients in Sweden - healthcare utilization, treatment, morbidity, and mortality using National register data. Seizure. 2017;53:4\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2017.10.005.","journal-title":"Seizure"},{"key":"3799_CR15","doi-asserted-by":"publisher","unstructured":"Strzelczyk A, Rosenow F, Zollner JP, Simon A, Wyatt G, Holland R, Schubert-Bast S. Epidemiology, healthcare resource use, and mortality in patients with tuberous sclerosis complex: A population-based study on German health insurance data. Seizure: Eur J Epilepsy. 2021;287\u201395. https:\/\/doi.org\/10.1016\/j.seizure.2021.06.027.","DOI":"10.1016\/j.seizure.2021.06.027"},{"key":"3799_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13023-020-01517-2","volume":"15","author":"WCY Chu","year":"2020","unstructured":"Chu WCY, Chiang LLW, Cha DCC, Wong WHS, Chan GCF. Prevalence, mortality and healthcare economic burden of tuberous sclerosis in Hong Kong: a population-based retrospective cohort study (1995\u20132018). Orphanet J Rare Dis. 2020;15:264. https:\/\/doi.org\/10.1186\/s13023-020-01517-2. https:\/\/ojrd.biomedcentral.com\/articles\/.","journal-title":"Orphanet J Rare Dis"},{"key":"3799_CR17","unstructured":"Pharmaceutical Interview Form. Afinitor Tablets 2.5\u00a0mg, 5\u00a0mg. Revis January 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291023"},{"key":"3799_CR18","unstructured":"Pharmaceutical Interview Form. Afinitor Dispersible Tablets 2\u00a0mg, 3\u00a0mg. Revised. January 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291023"},{"key":"3799_CR19","unstructured":"Pharmaceutical Interview Form. Rapamune Tablets 1\u00a0mg. Created August 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291035"},{"key":"3799_CR20","unstructured":"Pharmaceutical Interview Form. Rapamune Gel 0.2%. Revised June 2022. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/4291700"},{"issue":"5","key":"3799_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/jcpt.13434","volume":"46","author":"T Oka","year":"2021","unstructured":"Oka T, Narukawa M. Increased availability of drugs is correlated with the number of patients diagnosed thereafter: data analysis of 45 intractable diseases. J Clin Pharm Ther. 2021;46(5):1319\u201325. https:\/\/doi.org\/10.1111\/jcpt.13434.","journal-title":"J Clin Pharm Ther"},{"key":"3799_CR22","doi-asserted-by":"publisher","first-page":"103557","DOI":"10.1016\/j.ridd.2019.103557","volume":"97","author":"M Smith","year":"2020","unstructured":"Smith M, Manduchi B, Burke \u00c9, Carroll R, McCallion P, McCarron M. Communication difficulties in adults with intellectual disability: results from a National cross-sectional study. Res Dev Disabil. 2020;97:103557.","journal-title":"Res Dev Disabil"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03799-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03799-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03799-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:02:12Z","timestamp":1748019732000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03799-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3799"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03799-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective and anonymized design of the study, the requirement for informed consent was exempted. All patient data were thoroughly anonymized, ensuring the privacy and confidentiality of the participants. All enrollee data were anonymized by the Federation of National Health Insurance Association to protect participant confidentiality []. The study adhered to the principles of the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Shizuoka Graduate School of Public Health in Shizuoka, Japan (#SGUPH_2021_001_057).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}